Compare SATL & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATL | GERN |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | United States |
| Employees | 154 | 258 |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 821.1M |
| IPO Year | N/A | N/A |
| Metric | SATL | GERN |
|---|---|---|
| Price | $10.44 | $1.26 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $5.50 | $2.17 |
| AVG Volume (30 Days) | 7.4M | ★ 14.2M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $88.89 | $26.91 |
| Revenue Next Year | $56.98 | $43.75 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $1.04 |
| 52 Week High | $10.19 | $2.01 |
| Indicator | SATL | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 70.43 | 32.94 |
| Support Level | $3.18 | $1.24 |
| Resistance Level | N/A | $1.29 |
| Average True Range (ATR) | 0.96 | 0.09 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 96.80 | 10.42 |
Satellogic Inc is a vertically integrated Earth observation company that designs, manufactures, and operates satellite systems, delivering decision-grade insights at scale to government and commercial customers. Through an end-to-end production and operations model, it provides governments with flexible options across their journey toward sovereign Earth observation. From access to high-frequency imagery and managed space systems to full satellite ownership, to supporting autonomous data availability and long-term technological independence. It has monitoring and alert-driven workflows that help defense and intelligence agencies, civil governments, and commercial operators transition from reactive tasking to proactive decision-making, providing mission-critical data when needed.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.